IDSA recommends shorter antibiotic courses for adults with cUTIs who show clinical improvement on effective therapy.
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and ...
Exblifep is a combination product that consists of cefepime, a cephalosporin antibacterial, and enmetazobactam, a beta-lactamase inhibitor. The Food and Drug Administration (FDA) has approved Exblifep ...
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation ...
intravenous antibiotics Cefepime-enmetazobactam may be more effective than piperacillin-tazobactam in treating complicated UTI and acute pyelonephritis caused by organisms that produce ...
Carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa are a global threat to antimicrobial resistance and may be causative pathogens in cUTI. Cefepime-taniborbactam ...
Urinary tract infections (UTIs) represent a pervasive challenge in modern medicine, functioning as one of the most common reasons for outpatient antibiotic prescription. While the urinary system is ...
Researchers from Shaanxi Panlong Pharmaceutical Group Co. Ltd., Shaanxi Pioneer Biotech Co. Ltd. and affiliated organizations presented the discovery and preclinical characterization of novel ...
"The five factors with the highest odds of developing APN included obstructive and reflux uropathy, presentation to an acute care facility, urinary retention, history of UTI, and renal comorbidities.
A young male cadaveric kidney transplant developed delayed graft function. In addition to fever, serial allograft biopsies revealed progressive infiltration of polymorphonuclear leukocytes. After ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback